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ABSTRACT
High homocysteine (HCY) levels are a risk factor for osteoporotic fracture. Furthermore, bone quality and strength are compromised by
elevated HCY owing to its negative impact on collagen maturation. HCY is cleared by cystathionine b-synthase (CBS), the first enzyme in
the transsulfuration pathway. CBS converts HCY to cystathionine, thereby committing it to cysteine synthesis. A microarray experiment
on MC3T3-E1 murine preosteoblasts treated with 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] revealed a cluster of genes including the cbs
gene, of which the transcription was rapidly and strongly induced by 1,25(OH)2D3. Quantitative real-time PCR and Western blot analysis
confirmed higher levels of cbs mRNA and protein after 1,25(OH)2D3 treatment in murine and human cells. Moreover, measurement of
CBS enzyme activity and quantitative measurements of HCY, cystathionine, and cysteine concentrations were consistent with elevated
transsulfuration activity in 1,25(OH)2D3-treated cells. The importance of a functional vitamin D receptor (VDR) for transcriptional
regulation of cbs was shown in primary murine VDR knockout osteoblasts, in which upregulation of cbs in response to 1,25(OH)2D3 was
abolished. Chromatin immunoprecipitation on chip and transfection studies revealed a functional vitamin D response element in the
second intron of cbs. To further explore the potential clinical relevance of our ex vivo findings, human data from the Longitudinal Aging
Study Amsterdam suggested a correlation between vitamin D status [25(OH)D3 levels] and HCY levels. In conclusion, this study showed
that cbs is a primary 1,25(OH)2D3 target gene which renders HCY metabolism responsive to 1,25(OH)2D3.  2011 American Society for
Bone and Mineral Research.
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Introduction
The secosteroid prohormone vitamin D was discovered as anessential nutrient for the prevention of rickets.(1) Vitamin D is
indispensable to sustain calcium and phosphorus homeostasis
within the body. Classically, vitamin D is a potent facilitator of
calcium absorption in the small intestine and thereby necessary
for bone mineralization. 1,25-dihydroxyvitamin D3 [1,25(OH)2D3],
the active metabolite of vitamin D, is formed after two sequential
hydroxylations: 25-hydroxylation in the liver followed by a
second hydroxylation step in the kidney by the key activating
enzyme, CYP27B1. The combined presence of CYP27B1 and the
vitamin D receptor (VDR) in different tissues introduced the idea
of a paracrine function for 1,25(OH)2D3.
(2) The genomic actions of
1,25(OH)2D3 are mediated through the VDR, which acts as a
ligand-activated transcription factor. The heterodimer between
VDR and the retinoid X receptor (RXR) binds to vitamin D
responsive elements (VDREs) in the promoter region of target
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genes and therewith affects transcription. To unravel the diverse
actions of 1,25(OH)2D3 on different cell types, microarray
experiments have been performed in classic and nonclassic
target cells.(3) These results suggested that 1,25(OH)2D3 regulates
transcription of 3% of the mouse and human genome.(4) The
regulated genes are involved in mineral and bone homeostasis
but also in a number of other processes like cell cycle control and
differentiation.
The classic role of vitamin D in calcium absorption and bone
metabolism introduced the important role of vitamin D for the
treatment of rickets in infants and for prevention of weak bones
in the elderly. Combined supplements of vitamin D and calcium
are widely used to prevent and treat osteoporosis.(5) This disease
is a major public health problem, especially in older women.
Nutritional, lifestyle, hormonal, and genetic factors are involved
in the development of osteoporosis.(6) Among other factors, high
circulating levels of the nonproteinogenic, sulfur-containing
amino acid homocysteine (HCY) may contribute to osteoporotic
fracture risk.(7,8) With aging, the concentration of HCY increases
and easily exceeds the upper limit of 15mM, giving rise to
hyperhomocysteinemia. Bone quality and strength are compro-
mised by aggravated hyperhomocysteinemia as a result of
the negative impact of HCY on collagen cross-link formation
and maturation.(9,10) Moreover, high HCY levels change bone
homeostasis toward bone resorption, which further exacerbates
decreased bone quality.(11)
The transsulfuration pathway is necessary for HCY disposal
and culminates in the synthesis of cysteine (Fig. 1). The initial
step of this metabolic pathway is the condensation of HCY
and serine catalyzed by the vitamin B6-dependent enzyme,
cystathionine b-synthase (CBS). In the next step, cystathionine is
cleaved by the action of cystathionine gamma-lyase to cysteine,
which can be incorporated into proteins or used for the synthesis
of the antioxidant, glutathione (GSH).(12) Further, cysteine can be
oxidized to sulfate and excreted in the urine. Additionally,
the gaseous transmitter H2S is formed in the transsulfuration
pathway by enzymatic reactions catalyzed by cystathionine
gamma-lyase and CBS.(13,14) Mice deficient in cbs show severe
hyperhomocysteinemia accompanied by elevated levels of
reactive oxygen species (ROS) and a bone phenotype character-
ized by continuous progression of scoliosis and kyphosis.(15,16)
Humans suffering from hyperhomocysteinemia caused by
mutations in cbs or in genes of the remethylation cycle, such
as methylenetetrahydrofolate reductase (MTHFR) and methio-
nine synthase, or deficiencies in vitamins B6, B12, and folate
show vascular complications, connective tissue abnormalities,
and marfanoid symptoms and are also prone to osteoporotic
fractures.(17) The detrimental effects caused by elevated HCY
levels emphasize the necessity for a functional CBS enzyme.
Microarray analysis of MC3T3-E1 preosteoblast cells treated with
1,25(OH)2D3 or vehicle
(18) revealed transcriptional activation of a
cluster of genes in which cbs exhibited one of the strongest
responses. This observation prompted us to investigate a
possible link between HCY metabolism and 1,25(OH)2D3 action
via the upregulation of the cbs gene in bone.
Materials and Methods
Cell culture
MC3T3-E1 cells are preosteoblasts derived from C57BL/6 mice
(Riken Cell Bank, Ibaraki, Japan). The cells were maintained in a
modified essential medium (aMEM) with 2mM glutaMAX-I
supplemented with 10% heat inactivated fetal bovine serum
(FBS) (Biochrom AG, Berlin, Germany) and 100 units/mL penicillin
and 100mg/mL streptomycin (Invitrogen, Carlsbad, CA, USA). The
human osteosarcoma SaOS-2 cell line (Riken Cell Bank) is amodel
for human osteoblasts. The cells were maintained in Dulbecco’s
modified eagle medium (DMEM) with L-glutamine, pyruvate and
4.5 g/L glucose supplemented with 10% heat-inactivated FBS
(Biochrom AG) and 100 units/mL penicillin and 100mg/mL
streptomycin (Invitrogen). We isolated primary osteoblasts from
newborn VDR wild-type (wt) and VDR knockout (ko) mice from
calvaria by sequential digestion with 0.1% collagenase A and
0.2% dispase (Invitrogen) as described previously.(19) Cells
obtained from the second to fifth fraction were pooled and
cultured in aMEM with 2mM glutaMAX-I supplemented with
10% FBS and 100 units/mL penicillin and 100mg/mL streptomy-
cin. We seeded the cells at a density of 11,000 cells per cm2. The
next day, we treated the cells with 1,25(OH)2D3 (10
8M) (Sigma-
Aldrich, St. Louis, MO, USA) dissolved in ethanol or with ethanol
(vehicle) for distinct time intervals. The final concentration of
ethanol in medium was <0.01%.
Quantitative real-time polymerase chain reaction
We isolated total RNA for quantitative real-time polymerase
chain reaction (qRT-PCR) analysis with the High Pure RNA
Isolation Kit (Roche, Mannheim, Germany) following the
manufacturer’s instructions. One microgram RNA was reverse
Fig. 1. Transsulfuration pathway. CBS, cystathionine b-synthase; CTH,
cystathionine gamma-lyase the cofactor is vitamin B6. Mutations in cbs
or cth hamper the transsulfuration pathway and cause hyperhomocys-
teinemia. Also, a failure in remethylation (dependent on folate,
vitamin B12) or deficiencies in vitamins B6, B12, and folate cause hyper-
homocysteinemia, which is associated with impaired cross-link forma-
tion, connective tissue abnormalities and increased risk of osteoporosis.
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transcribed using SuperScriptII (Invitrogen). We diluted the
resulting cDNA 1/10 and used it as a template in PCR reactions,
applying the 7500 Fast Real Time PCR System (Applied
Biosystems, Inc., Foster City, CA, USA). We purchased PCR
primers and fluorogenic probe for mouse cbs from Eurogentec
(Seraing, Belgium). The gene-specific primers and probe we used
are as follows: cbs-forward: 50-GCAGCGCTGTGTGGTCAT-30,
cbs-reverse: 50-CCATTTGTCACTCAGGAACTTG-30, cbs-probe: 50-
CCTGCCTGACTCTGTGCGGAACTA-30. In order to deduce the
absolute copy number within the examined sample, we used a
defined standard clone in a serial dilution. We used these data to
calculate a standard curve and to assure assay specificity and
efficiency. The expression of the housekeeping gene b-actin
served as internal control and was used to normalize gene
expression.
Western blot analysis
We isolated total protein from MC3T3-E1 cells treated with
1,25(OH)2D3 (10
8M) or vehicle. Cells were lysed with a buffer
containing 50mM Tris HCl, pH 8 (Sigma-Aldrich); 150mM NaCl
(Thermo Fisher Scientific, Pittsburgh, PA, USA); 0.1% sodium
dodecyl sulfate (SDS) (Thermo Fisher Scientific); 1% IGEPAL CA-
630 (Sigma-Aldrich); and 0.5% sodium deoxycholate (Merck,
Darmstadt, Germany). We sonicated the cell lysate for
2 10 seconds at cycle 1 and amplitude 80 with the UP50H
Ultrasonic Processor (Hielscher Ultrasound Technology, Teltow,
Germany). Thereafter, we centrifuged thematerial for 10minutes
at 14,000 rpm and used the supernatant for Western blotting.
Twenty-five micrograms (mg) of protein was boiled in sample
buffer and reducing agent (Invitrogen) and subsequently
separated by SDS-PAGE using 4–12% polyacrylamide gels
(Invitrogen) and transferred to a nitrocellulose membrane (GE
Healthcare, Piscataway, NJ, USA). Themembrane was blocked for
1 hour with TBS (10mM Tris-HCl; pH 7.6; 150mM NaCl)
containing 1% casein (Sigma-Aldrich) and 1% Tris (1M). After
blocking, we incubated the membrane with slight agitation
overnight at 4 8C with the primary antibody (rabbit anti-human
CBS 1/500, developed in the lab of Prof. R. Banerjee, Ann Arbor,
MI, USA). Incubation with a horseradish peroxidase (HPR)-
conjugated secondary antibody (Dako, Glostrup, Denmark) was
performed for 1 hour at room temperature. All blots were
developed by enhanced chemiluminescence (Perkin Elmer,
Waltham, MA, USA).
Cystathionine b-synthase activity assay
CBS activity was measured by the ninhydrin assay as described
by Vitvitsky and colleagues.(20) In brief, cells were homogenized
using a mortar cooled with liquid nitrogen and subsequently
150mg of the obtained cell powder was mixed with 350mL
1.15% KCl solution (Merck). After centrifugation (15,000 g for
20minutes at 48C) the supernatant was aspirated. For the assay,
100mL sample supernatant, 10mL Tris-HCl (1M), 2mL pyridoxal
phosphate (1.2mM in 0.1M Tris, pH 8.3) (Sigma-Aldrich) and
20mL propargylglycine (25mM in 0.1M Tris, pH 8.3) (Sigma-
Aldrich) were mixed and incubated for 15minutes at 378C.
Subsequently, 20mL serine (1M in 0.1M Tris, pH 8.3) (Fluka by
Sigma-Aldrich, Steinheim, Germany) and 40mL HCY (0.75M in
water) (Sigma-Aldrich) solutions were added, mixed and
incubated for 60minutes at 378C. We stopped the reaction
with 20mL of 50% trichloroacetic acid (Merck). We centrifuged
the samples and discarded the pellets. We mixed the
supernatant (100mL) with 825mL ninhydrin reagent (1 g
ninhydrin [ACROS Organics by Thermo Fisher Scientific],
dissolved in 100mL glacial acetic acid [Sigma-Aldrich] mixed
with 33mL molten crystal phosphoric acid [Sigma-Aldrich]). The
mixture of sample and reagent was incubated for 5minutes in
boiling water followed by 2minutes on ice and 20minutes at
room temperature. We measured the optical density of the
resulting solution (455 nm) against a blank sample. We assayed
all samples in duplicate and calculated CBS activity using a
calibration curve generated with cystathionine (2–10mM)
(Sigma-Aldrich).
Chromatin immunoprecipitation on chip
Data obtained for the cbs gene locus in the MC3T3-E1 cell line
were derived from a genome-wide chromatin immunoprecipita-
tion (ChIP)-on-chip analysis previously reported by Meyer and
colleagues.(21) In brief, we performed ChIP-on-chip analyses
using HD2-formatted mouse whole genome tiling arrays (Roche-
NimbleGen Inc.). The data were extracted using the NimbleScan
software (version 2.5) and normalized using locally weighted
scatter-plot smoothing (LOWESS) normalization in R. The log2
ratio of test versus experimental data were calculated for each
point and peaks were called using CMARRT algorithms. Data
shown are representative of two or more ChIP-on-chip analyses
performed for each experimental set. All data were visualized
using Gbrowse (www.gmod.org/wiki/Gbrowse). Classical ChIP
experiments for VDR, RXR, and acetylated histone 4 (H4-Ac) were
performed to confirm the ChIP-on-chip results. These experi-
ments were done as previously described.(21,22) We treated
MC3T3-E1 cells with 1,25(OH)2D3 (10
7M). The cell lysates
used in these ChIP and ChIP-on-chip experiments were from
independent experiments.
Transfections
We transfected MC3T3-E1 cells either with 200 ng empty
pGL3basic luciferase reporter vector (Promega, Madison, WI,
USA) or pGL3basic vector, in which luciferase expression is under
control of a wild-type 1456-bp fragment. This fragment
originates from the second cbs intron present on the murine
chromosome 17 between nucleotide 31,359,592 and 31,361,047.
We retrieved all the murine genome data from the University of
California, Santa Cruz (UCSC) genome browser and based on the
Build 36 ‘‘essentially complete’’ assembly (MM8) by the National
Center for Biotechnology Information (NCBI) and the Mouse
Genome Sequencing Consortium. Furthermore, we used a 1456-
bp fragment with a mutation in the direct repeat 3 (DR3)-type
VDRE. We performed mutations with the QuickChange II Site-
Directed Mutagenesis kit (Stratagene, Santa Clara, CA, USA).
Additionally, we co-transfected cells with 20 ng of the b-
galactosidase expression vector pcDNA3.1()/Myc-His/lacZ
(Invitrogen) to assess transfection efficiency. We performed
the transfection using Fugene 6 transfection reagent (Roche)
following the manufacturer’s instructions. After transfection, we
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cultured the cells overnight and treated them the following day
with 1,25(OH)2D3 (10
8M) or vehicle. After 24 hours, we rinsed
the cells in PBS and lysed themwith 100mL of the Reporter Gene
Lysis Buffer (Roche). We used cell extracts to measure luciferase
activity with the Luciferase Assay System (Promega); the
obtained values were normalized for the efficiency of transfec-
tion using b-galactosidase activity detected by the Tropix1
Galacto-Light Plus System (Applied Biosystems). We measured
luciferase and b-galactosidase activity by the Luminoskan Ascent
luminometer (Thermo Fisher Scientific). We performed all
experiments in triplicate and repeated them three to five times.
Metabolite analysis
For the measurement of HCY, cystathionine, and cysteine in cell
lysates and growth medium, we seeded MC3T3-E1 cells in 60-
cm2 dishes (11,000 cells per cm2). Cells were left overnight to
attach. The next day, we treated the cells with 1,25(OH)2D3
(108M) or vehicle. To determine baseline levels, we prepared
cell lysates from cells that were not treated and measured
metabolite concentrations. After 48 hours or 72 hours incuba-
tion, we scraped cells and centrifuged the cell-medium
suspension for 10minutes at 1500 g. Subsequently, we aspirated
the medium and used it for further analysis. Additionally, we
froze an aliquot of fresh medium and used it to determine the
standard amino acid content. We resuspended the cell pellet in
500mL distilled water and subjected it to a freeze-thaw cycle and
to 5minutes sonication with the Bioruptor Sonicator (Diagenode,
Lie`ge, Belgium). Finally, we measured the concentrations of the
cellular metabolites HCY, cysteine, and cystathionine by gas
chromatography–mass spectrometry (Dr. Sally Stabler, Colorado
University Medical Center, Aurora, CO, USA) as described
before.(23) In order to normalize obtained measurements, cell
samples that had been treated with vehicle or 1,25(OH)2D3
(108M) were analyzed for protein content. After washing with
PBS, we lysed cells and determined protein content as described
before (Western blot analysis). For GSHmeasurements, we rinsed
MC3T3-E1 cells twice with cold PBS and subsequently scraped
them in 100mL PBS. The cell suspension was subject to GSH
measurement by HPLC as described before.(24)
Longitudinal Aging Study Amsterdam cohort
The Longitudinal Aging Study Amsterdam (LASA) is a cohort
study of elderly people aged 55 to 85 years at the start in 1992.
Persons recruited were a random sample stratified by age, sex,
and expected 5-year mortality rate drawn from the population
registers of 11 municipalities in three regions of the Netherlands.
In total, 3107 persons were enrolled in the baseline examination
in 1992–1993. Serum 25-hydroxyvitamin D3 [25(OH)D3] was
measured in samples obtained in 1995–1996 in all participants of
65 years and older as of January 1, 1996. The blood samples were
immediately centrifuged and kept frozen at20 8C until analysis
in 1999. Serum 25(OH)D3 was measured with a competitive
protein binding assay (Nichols Diagnostics, San Juan Capistrano,
CA, USA) with an interassay coefficient of variation of 10%. For
the present study, we selected 1264 subjects with normal renal
function; ie, with creatinine levels between 50 and 150mM. We
applied a regression model to evaluate the relation between
25(OH)D3 and HCY in 1264 subjects. The multivariable model
contained age (linear), gender, creatinine level (linear), and
25(OH)D3 level (nonlinear) as predictors. In the analysis, no
interactions were included. We performed all analyses using the
statistical package SAS (version 9.2; SAS Institute, Cary, NC, USA).
Values of p smaller than 0.05 were considered significant.
Results
Effects of 1,25(OH)2D3 on cbs gene expression
In order to study the effects of 1,25(OH)2D3 on the expression of
cbs, we cultured MC3T3-E1 mouse preosteoblasts in the
presence of 1,25(OH)2D3 (10
8M) and monitored transcript
levels of cbs at different time points. Cbs mRNA levels increased
as early as 3 hours after treatment and showed a 350-fold
Fig. 2. Transcript levels of cbs are upregulated by 1,25(OH)2D3 in murine
MC3T3-E1 and primary osteoblasts. (A) Transcript levels were determined
by qRT-PCR at different time points after treatment with 1,25(OH)2D3
(108M). Each data point represents the ratio of cbs levels normalized
over b-actin, relative to the normalized cbs levels of vehicle-treated cells
(1 hour). The data are the mean SEM of four independent experiments.
The overall upregulation of cbs expression by 1,25(OH)2D3 was found to
be significant according to ANOVA (p< 0.05). (B) Cbs expression mea-
sured by qRT-PCR in primary osteoblasts treated for 24 hours with vehicle
or 1,25(OH)2D3 (10
8M). Osteoblasts originate from VDR wild-type (VDR
wt; n¼ 6) and VDR knock out (VDR ko; n¼ 5) mice. Bars represent the
mean SEM of each group. The expression of cbs in 1,25(OH)2D3-treated
VDR wt osteoblasts is significantly different from the other groups
displayed, according to ANOVA followed by a Bonferroni multiple-
comparison test (ap< 0.05).
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induction at 72 hours compared to control conditions at 1 hour
(Fig. 2A). Cbs levels did not change in vehicle-treated cultures.
Further, to investigate whether a functional VDR is required for
the induction of cbs transcript levels by 1,25(OH)2D3, we
measured cbs cDNA levels in VDR ko murine primary osteoblasts
treated for 24 hours with 1,25(OH)2D3 (10
8M) or with vehicle.
The cbs cDNA levels in VDR ko osteoblasts did not change after
incubation with 1,25(OH)2D3, whereas in osteoblasts from VDR
wt mice cbs expression was strongly enhanced by 1,25(OH)2D3
(more than eightfold) (Fig. 2B).
Transcriptional activation of cbs by vitamin D receptor
Next, we used a ChIP-on-chip approach to identify a VDR binding
site within the cbs gene. 1,25(OH)2D3-treated MC3T3-E1 cells
showed robust binding of VDR, RXR, and the presence of H4-Ac
at a 1-kilobase (kb) region approximately 6 kb downstream of the
cbs transcription start site (chromosome 17 between nucleotide
31,359,000 and 31,361,000) (Fig. 3A). The detected receptor
binding suggested the presence of a VDRE in the second intron
of the cbs gene. In silico screening revealed a putative VDRE with
a classical DR3 motif containing two hexameric sequences
separated by a 3-bp spacer within the second cbs intron located
at þ5983 to 5998 relative to the cbs transcription start site
(ENSMUST00000067801). Subsequently, we applied the classical
ChIP approach to confirm the ChIP-on-chip data for VDR, RXR,
and H4-Ac (Fig. 3A). Next, a 1456-bp fragment of the cbs gene
(position þ4862 to þ6318 relative to transcription start site or
nucleotide 31,359,592 and 31,361,047 on chromosome 17),
which contained the putative VDRE, was cloned into a pGL3basic
luciferase reporter plasmid to investigate the transactivating
activity of 1,25(OH)2D3 in transient transfection experiments
(Supporting Fig. S1). Relative to vehicle-treated cells, incubation
with 108M 1,25(OH)2D3 resulted in an eightfold increase in
Fig. 3. Transcriptional activation of the cbs gene by VDR bound to a classical DR3-type VDRE. (A) ChIP-on-chip was used to determine transcription factor
binding. The genomic location for the cbs gene is shown for chromosome 17 with genomic base pairs given in kilobases (k). Increased binding is indicated
by enhanced readout (peaks) at the murine DNA sequence at chromosome 17 between nucleotide 31,359,000 and 31,361,000. The assay was performed
on chromatin from vehicle- (Veh/Input) and 1,25(OH)2D3 (1.25/Input)-treated MC3T3-E1 cells with antibodies against VDR, RXR, and H4-Ac. Data are
displayed as log2 ratios (log2 R). Next to the murine DNA sequence, the results of classical ChIP experiments confirm the ChIP-on-chip data. Bars are the
mean SEM of three independent experiments. ap< 0.05 according to Student’s t test). (B) MC3T3-E1 cells were transfected with empty pGL3basic (neg)
or pGL3basic containing the wild-type (wt) or mutated (mutDR3.1 or mutDR3.2) fragment of the second cbs intron (murine chromosome 17 between
nucleotide 31,359,592 and 31,361,047) and with a b-galactosidase-expressing construct. After 24 hours, cells were treated with 1,25(OH)2D3 (10
8M) or
vehicle and after another 24 hours luciferase and b-galactosidase were measured. Luciferase activities were normalized to b-galactosidase activities.
RLU¼ relative luciferase units. Bars are the mean SEM of at least three independent experiments. (C) Mutated fragments were obtained by substitution
of 4 nucleotides (GGGTTG to ATACTG) within the 30 hexamer of the VDRE (mutDR3.1) and the 50 hexamer of the VDRE (AGTTCA to TAACCA (mutDR3.2). The
relative luciferase activity (RLU) in 1,25(OH)2D3-treated cells transfected with the wt construct is significantly different from the other measurements
displayed, according to ANOVA followed by a Bonferroni multiple-comparison test (ap< 0.05).
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luciferase activity in MC3T3-E1 cells transfected with the cbs DR3-
type VDRE-containing reporter construct (Fig. 3B). To confirm
that the transactivation was driven by the putative VDRE, we
made two reporter constructs, which containedmutations within
the DR3-type VDRE (Fig. 3C). In one mutant, the 30 hexamer
sequence GGGTTGwasmutated to ATACTG (mutDR3.1), whereas
in the second, the 50 hexamer AGTTCA was altered to TAACCA
(mutDR3.2). As shown in Figure 3B, mutation of the VDRE within
the cbs promoter construct (mutDR3.1 or mutDR3.2) completely
abolished the responsiveness to 1,25(OH)2D3.
Effect of 1,25(OH)2D3 on CBS protein and
enzymatic function
Western blot analysis showed a strong increase in CBS levels at
24 hours after 108M 1,25(OH)2D3 treatment and at later time
points (Fig. 4A). The induction of CBS by 1,25(OH)2D3 was
observed in both amurine (MC3T3-E1) and a human (SaOS-2) cell
line. To investigate whether 1,25(OH)2D3 treatment resulted in
increased CBS activity, we measured the synthesis of cystathio-
nine from the substrates, HCY and serine, in MC3T3-E1 cell
lysates at baseline (0 hours) and after 48 hours and 72 hours after
treatment. CBS activity was 2.6- and 1.9-fold higher at 48 hours
and 72 hours, respectively, in cell lysates derived from
1,25(OH)2D3-treated cells compared to vehicle-treated controls
(Fig. 4B).
Effect of 1,25(OH)2D3 on the amino acids of the
transsulfuration pathway
Next, we investigated targeted metabolite changes by deter-
mining the concentrations of HCY, cystathionine, cysteine, and
GSH in MC3T3-E1 cell lysates (Fig. 5). The HCY concentration was
lower in 1,25(OH)2D3-treated cells compared to vehicle-treated
controls (30% and 26% versus control after 48 hours and
72 hours, respectively; Fig. 5A). In contrast, the concentration of
cystathionine (112% and 74% versus control after 48 hours
and 72 hours, respectively; Fig. 5B) and cysteine (23% and 24%
versus control after 48 hours and 72 hours; Fig. 5C) increased
in 1,25(OH)2D3-treated cells compared to control conditions,
whereas GSH decreased in 1,25(OH)2D3-treated cells (28%
and 44% versus control after 48 hours and 72 hours,
respectively; Fig. 5D). We further investigated the concentrations
of amino acids in the culture medium (Fig. 6). Whereas the
concentration of HCY (39% and 43% versus control after
48 hours and 72 hours; Fig. 6A) was decreased significantly, the
concentration of cystathionine (115% and 152% versus control
after 48 hours and 72 hours, respectively; Fig. 6B) and cysteine
(91% and 171% versus control after 48 hours and 72 hours,
respectively; Fig. 6C) was significantly higher after 1,25(OH)2D3
treatment. Metabolite concentrations in cell lysates and medium
Fig. 4. (A) Western blot analysis of CBS expression on total lysates of
vehicle- and 1,25(OH)2D3-treated murine preosteoblasts (MC3T3-E1) and
human osteosarcoma cells (SaOS-2) at different time points; b-actin was
used as loading control. (B) The enzymatic activity of CBS is depicted at
0 hours and after 48 hours and 72 hours in vehicle- and 1,25(OH)2D3-
treated cells. The mean SEM from six independent experiments is
shown. The overall changes in CBS enzymatic activity by 1,25(OH)2D3
were found to be significant according to ANOVA (p< 0.05).
Fig. 5. Changes in metabolite composition in 1,25(OH)2D3-treated
MC3T3-E1 preosteoblasts. The concentrations of (A) HCY, (B) cystathio-
nine, (C) cysteine, and (D) GSH are depicted at 0 hours and after 48 hours
and 72 hours in vehicle- and 1,25(OH)2D3-treated cells. Metabolites were
measured in cell lysates. Each data point represents the mean SEM of
three or four duplicate measurements. The overall changes in HCY,
cystathionine, cysteine, and GSH levels by 1,25(OH)2D3 were found to
be significant according to ANOVA (p< 0.05).
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from 1,25(OH)2D3-treated cultures were always significantly
different from those in vehicle-treated cultures according to
analysis of variance (ANOVA) (p< 0.05).
Vitamin D status and HCY levels
In order to assess whether vitamin D status is correlated with
HCY levels in vivo, we investigated the LASA cohort, a human
population-based study. We analyzed HCY, 25(OH)D3, and
creatinine (creatinine levels between 50 and 150mM) levels in
1264 individuals between 65 and 88 years of age. We used a
flexible regression model that allows for nonlinearity to analyze
the relation between HCY and 25(OH)D3 levels. A significant
correlation (p¼ 0.0015) between HCY and 25(OH)D3 levels, the
marker of choice for vitamin D status, was observed and the
relation was U-shaped (Fig. 7), with lowest HCY levels when
25(OH)D3 status was between 50 and 60 nM (20–24 ng/mL). To
estimate this transition point, we applied a two-phase linear
model (in a multivariable setting correcting for age, gender,
and creatinine), resulting in an estimated cut-point of
51.8 nM (20.72 ng/mL) (95% confidence interval, 40.6–62.9).
The Spearman correlation equalled 0.103 (p¼ 0.009) before
the cut-point and 0.078 (p¼ 0.054) beyond the cut-point,
respectively. A statistically significant difference in HCY
levels between males and females was not shown (p¼ 0.57);
a significant correlation between HCY and creatinine levels
(p< 0.0001) was found.
Discussion
This study provides evidence that cbs is a direct target of VDR
regulation and suggests that a functional transsulfuration
pathway is present in osteoblasts. Our analysis showed that
basal levels of cbs mRNA and protein in MC3T3-E1 murine
preosteoblasts were low and increased strongly after incubation
with 1,25(OH)2D3. A functional VDR was required for the
induction of cbs mRNA levels, since the expression of cbs was
not increased in VDR ko primary osteoblasts after 1,25(OH)2D3
treatment. The direct regulation of cbs by 1,25(OH)2D3 was
further established by ChIP-on-chip and classic ChIP experiments
and additionally by ChIP-sequencing (data not shown). All these
experiments show VDR binding together with RXR and
acetylated histone H4 in the intergenic region of the cbs gene.
This observation led to the identification of a functional VDRE in
the second cbs intron. The induction of cbs expression by
1,25(OH)2D3 was not limited to MC3T3-E1 cells but was also
shown in a number of different murine cell lines like ATDC5
chondrocytes, bone marrow stromal ST-2 cells, in GR mammary
carcinoma cells, but also in primary murine osteoblasts, bone
marrow stromal, and kidney cells (data not shown). The liver
expresses the highest CBS protein levels and activity.(25)
Nevertheless, we could not detect an effect of 1,25(OH)2D3 on
the expression of cbs in hepatocytes (data not shown); however,
the basal cbs expression in these cells is comparable to cbs
expression in 1,25(OH)2D3-treated osteoblasts. The absence of
1,25(OH)2D3-driven cbs regulation in liver is likely as a result of
the lack of sufficient VDR expression in this tissue.(26) In liver,
regulation of cbs relies on different transcription factors and
regulators. Among these is the allosteric activator S-adenosyl-
methionine, which can increase CBS activity twofold to threefold;
it also stabilizes the protein against degradation.(27,28) In
addition, the binding of a number of different transcription
factors within the cbs promoter, such as the constitutively active
specificity protein 1 and factor NF-Y, was reported.(29) Taken
together, this suggests that the effects of 1,25(OH)2D3 on the
HCY metabolism are local, affecting osteoblasts and other VDR-
expressing cells directly. This assumption was further supported
by experiments performed in VDR wt and VDR ko mice (data not
shown), in which no differences in the total plasma HCY levels
were detected. This is probably attributed to the before
mentioned natural lack of VDR expression in the liver(26) and
an unaffected hepatic HCY metabolism. For MC3T3-E1 pre-
osteoblasts we could conclusively show that cbs expression was
directly driven by 1,25(OH)2D3 activating VDR bound to a
classical DR3-type VDRE. The 1,25(OH)2D3-induced increase in
Fig. 6. Changes of amino acid content in growth medium of vehicle- or
1,25(OH)2D3-treated cells. The concentrations of (A) HCY, (B) cystathio-
nine, and (C) cysteine are depicted at baseline and after 48 hours and
72 hours of vehicle or 1,25(OH)2D3 treatment. Measurements were nor-
malized by subtraction of the amino acid concentration present in fresh
medium. Each data point represents the mean SEM of four duplicate
measurements. The overall decrease of HCY levels and increase of
cystathionine and cysteine levels by 1,25(OH)2D3 were found to be
significant according to ANOVA (p< 0.05).
Fig. 7. Relation between 25(OH)D3 and homocysteine obtained from a
regressionmodel on 1264 subjects with creatinine levels between 50 and
150mM. Dotted lines represent pointwise 95% confidence intervals (CI)
for the mean relation, which is depicted for an ‘‘average’’ subject;
ie, having a creatinine level of 100mM and being 75 years of age.
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cbs expression in osteoblasts was accompanied by an increase
in CBS protein levels and enzymatic activity. The changes
suggest an increased production of transsulfuration products in
1,25(OH)2D3-stimulated osteoblasts. Furthermore, the lower level
of CBS substrate (HCY) and higher concentrations of transsul-
furation pathway products (cystathionine and cysteine) in
1,25(OH)2D3-treated MC3T3-E1 preosteoblasts and in the culture
medium are consistent with an enhanced flux through the
transsulfuration pathway. These changes may have several
implications, since increased cysteine levels after 1,25(OH)2D3
treatment could be used for the increased production of
GSH, H2S, or taurine, or used in protein synthesis.
(12) However, we
found decreased intracellular GSH levels in 1,25(OH)2D3-treated
MC3T3-E1 cells. This finding is in line with the observation that
the concentration of GSH is unchanged and the level of the GSH
breakdown product, cysteinyl-glycine, is decreased in transgenic
mice with higher enzymatic CBS activity.(30) On the contrary,
increased GSH levels have been shown in primary rat astrocytes
treated with lipopolysaccharide (LPS) and 1,25(OH)2D3 owing to
the stimulating effect of 1,25(OH)2D3 on the expression and
activity of the enzyme gamma-glutamyl transpeptidase.(31)
Moreover, increased CBS activity is also linked to enhanced
HCY elimination and may have implications for the maintenance
of bone quality and strength. It has been shown that HCY
accumulates specifically in bone by binding to collagen.(32)
Vitamin D may counteract the effects of high HCY levels on bone
by increased CBS synthesis and enzymatic activity. The effects of
1,25(OH)2D3 on CBS were not limited to murine bone cells but
were also observed in human osteosarcoma SaOS-2 cells, a cell
line with osteoblastic features.(33)
To further explore the potential clinical relevance of the
ex vivo data, and to evaluate the relation between serum
25(OH)D3 and HCY levels without making any a priori
assumptions about the type of relation, we used a flexible
regression modeling approach. We used data from the LASA
study, which contains a random population-based sample of
older men and women aged 65 to 88 years, for analysis. Serum
25(OH)D3 is the best indicator of overall vitamin D status,
because this measurement reflects total vitamin D from dietary
intake and sunlight exposure, as well as the conversion of
vitamin D from adipose stores in the liver.(34) The aged human
population is generally characterized by elevated HCY, low
vitamin D levels and an increased susceptibility to osteoporotic
fracture, especially in women. Based on the relationship between
serum 25(OH)D3, bone mineral density, bone turnover, lower
extremity function, and falls, 50 nM (20 ng/ml) is considered
an appropriate serum 25(OH)D3 threshold to define vitamin D
insufficiency.(35) In line with this 50-nM threshold, several studies
have suggested that vitamin D supplementation may be most
effective in reducing fractures and falls in institutionalized elderly
persons, in whom serum levels of 25(OH)D3 are often below
50 nM.(36) In our analysis of LASA samples, we found a significant,
creatinine-adjusted relationship between HCY and serum
25(OH)D3 levels. In particular, levels below 50 nM were
associated with an increase in circulating HCY (Spearman
correlation of0.013 before the cut-point of 51.8 nM), consistent
with the assumption that vitamin D insufficiency may potentially
contribute to the amount of HCY in serum. To further unravel the
25(OH)D3–HCY relationship, more data are needed on the effects
of vitamin D supplementation on serum HCY. The data showed
no difference in HCY levels between males and females but
confirmed the significant positive relationship between HCY and
creatinine levels, which is in line with previously reported
evidence that HCY levels increase with the degree of renal
insufficiency.(37) Elevated HCY levels are correlated with a
number of different diseases and detrimental health implica-
tions, such as osteoporotic fractures or rising risk of stroke.(38)
In osteoblast cells, it was shown that high HCY levels inhibit
the expression of enzymes necessary for enzymatic collagen
cross-link.(39,40) Moreover, HCY binds to cross-link precursors and
might result in weaker bone and reduced bone quality.(41)
Therefore, high HCY levels have negative effects on collagen
cross-linking and affect bone in a negative way. The possibility to
lower HCY levels systemically or locally should impact bone
health in a positive manner.
From our data, we can conclude that there is an association
between the 25(OH)D3 status and the amount of HCY in serum.
This effect is relatively small compared to the HCY lowering
effects of other vitamins, such as the B vitamins but 1,25(OH)2D3
may support the action of folic acid, vitamin B6, and B12 in
lowering high HCY levels.(42) Nevertheless, this beneficial effect
of 1,25(OH)2D3 on HCY levels adds to the multitude of positive
effects linked to an optimal vitamin D status.
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